RxDoctor Payments Data

Laurie Green, MD

Obstetrics · San Francisco, CANPI 1679641658

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.7% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations.

$2,092in general payments, 2019–2025

Across 77 payments — averaging $27.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$281
  • Biogen$270
  • AbbVie$209
  • Hologic Sales And Service, LLC$135
  • Organon$129
  • AstraZeneca$125
  • plus $943 from 20 others

What the payments were for

  • Food & beverage$1,98195%
  • Education$1115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,092 in reported general payments places this provider in the 70th percentile of 119 obstetrics providers in California.

See all obstetrics providers in California

Medicare billing

Part B allowed, 2024
$63,456
Medicare patients
309
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol215$23,600
Estradiol (Twice Weekly)Estradiol193$21,540
ProgesteroneProgesterone, Micronized166$7,431
YuvafemEstradiol34$6,298
DottiEstradiol28$3,413
ValacyclovirValacyclovir Hcl30$1,827
Clindamycin Phosphate14$1,771
Estradiol (Once Weekly)Estradiol17$1,146
LyllanaEstradiol13$922
Acyclovir27$650
Medroxyprogesterone Acetate21$185
Alendronate Sodium13$183
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$88
Misoprostol11$33

Paid to pharmacies, not to this prescriber.

Other obstetrics in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →